Zobrazeno 1 - 10
of 108
pro vyhledávání: '"Evgueni L Saenko"'
Autor:
Jose Ruiz, Diana Kouiavskaia, Molly Migliorini, Susan Robinson, Evgueni L. Saenko, Natalia Gorlatova, Donghua Li, Daniel Lawrence, Bradley T. Hyman, Karl H. Weisgraber, Dudley K. Strickland
Publikováno v:
Journal of Lipid Research, Vol 46, Iss 8, Pp 1721-1731 (2005)
Apolipoprotein E (apoE) associates with lipoproteins and mediates their interaction with members of the LDL receptor family. ApoE exists as three common isoforms that have important distinct functional and biological properties. Two apoE isoforms, ap
Externí odkaz:
https://doaj.org/article/ccd16cc9ff0f46a5b185bb9560a19daf
Autor:
Suryasarathi Dasgupta, Ana Maria Navarrete, Sebastien André, Bharath Wootla, Sandrine Delignat, Yohann Repessé, Jagadeesh Bayry, Antonino Nicoletti, Evgueni L. Saenko, Roseline d’Oiron, Marc Jacquemin, Jean-Marie Saint-Remy, Srini V. Kaveri, Sebastien Lacroix-Desmazes
Publikováno v:
Haematologica, Vol 93, Iss 1 (2008)
Background The development of factor VIII (FVIII) inhibitors remains the major hurdle in the clinical management of patients with hemophilia A. FVIII uptake by professional antigen-presenting cells (APC) is the first step involved in initiation of im
Externí odkaz:
https://doaj.org/article/17d0f28f359c4df2b641a883bc33ad09
Publikováno v:
Seminars in Thrombosis and Hemostasis. 35:735-751
Development of inhibitory antibodies (inhibitors) to factor VIII (FVIII) is the most serious adverse event in replacement therapy of hemophilia A patients. The etiology and management of this condition remain major challenges for both researchers and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c53929822bb986233f4d5260d6c1ad7c
https://doi.org/10.1055/s-0029-1245106
https://doi.org/10.1055/s-0029-1245106
Autor:
Roseline d'Oiron, Antonino Nicoletti, Ana Maria Navarrete, Marc Jacquemin, Bharath Wootla, Evgueni L. Saenko, Jean-Marie Saint-Remy, Sébastien Lacroix-Desmazes, Jagadeesh Bayry, Srini V. Kaveri, Sébastien André, Yohann Repessé, Suryasarathi Dasgupta, Sandrine Delignat
Publikováno v:
Haematologica. 93:83-89
Background The development of factor VIII (FVIII) inhibitors remains the major hurdle in the clinical management of patients with hemophilia A. FVIII uptake by professional antigen-presenting cells (APC) is the first step involved in initiation of im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::934db7bbfa22599ebacff9a839bd8355
https://doi.org/10.3324/haematol.11535
https://doi.org/10.3324/haematol.11535
Autor:
Alexey V. Khrenov, Evgueni L. Saenko, Burkhardt Laufer, Sebastian Knör, Charlotte A. E. Hauser, Horst Kessler
Publikováno v:
Journal of Medicinal Chemistry. 50:4329-4339
Hemophilia A, one of the most severe bleeding disorders, results from an inherited deficiency of factor VIII (FVIII) function. Treatment by injection of FVIII has been a common procedure for decades. Nevertheless, the production and purification of F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc2823c60acc399629dbae31d5f0e802
https://doi.org/10.1021/jm070304x
https://doi.org/10.1021/jm070304x
Publikováno v:
Current Pharmaceutical Design. 13:1457-1467
At present, computer-assisted molecular modeling and virtual screening have become effective and widely-used tools for drug design. However, a prerequisite for design and synthesis of a therapeutic agent is determination of a correct target in the me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f13b801f65306c68c1169a6b72a00faf
https://doi.org/10.2174/138161207780765936
https://doi.org/10.2174/138161207780765936
Autor:
Alexey V. Khrenov, Dudley K. Strickland, Irina Mikhailenko, Evgueni L. Saenko, Olav M. Andersen, Midori Shima, Andrey G. Sarafanov, Natalya M. Ananyeva, Evgeny M. Makogonenko
Publikováno v:
Thrombosis and Haemostasis. 98:1170-1181
SummaryCatabolism of coagulation factorVIII (FVIII) is mediated by lowdensity lipoprotein receptor-related protein (LRP). The ligandbinding sites of LRP are formed by complement-type repeats (CR), and CR clusters II and IV bind most of LRP ligands. F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44b458e2773912998bcde45268989329
https://doi.org/10.1160/th07-05-0353
https://doi.org/10.1160/th07-05-0353
Autor:
Natalya M. Ananyeva, Evgueni L. Saenko
Publikováno v:
Haemophilia. 12:15-22
Summary The present review discusses the current concept of receptor-mediated clearance of coagulation factor VIII (FVIII) from the circulation in vivo, which is one of the mechanisms regulating FVIII level in plasma. Several lines of experimental ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95c223472ad475cc555efdcf2e440349
https://doi.org/10.1111/j.1365-2516.2006.01329.x
https://doi.org/10.1111/j.1365-2516.2006.01329.x
Autor:
Evgueni L. Saenko, Steven W. Pipe
Publikováno v:
Haemophilia. 12:42-51
The reduced mortality, improved joint outcomes and enhanced quality of life, which have been witnessed in the developed world for patients with haemophilia, have been an outstanding achievement. Advancements in biotechnology contributed significantly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1191114fc82abae0ebb58d663ded5a3f
https://doi.org/10.1111/j.1365-2516.2006.01260.x
https://doi.org/10.1111/j.1365-2516.2006.01260.x
Autor:
Midori Shima, Yoshihiko Sakurai, Katsumi Nishiya, Ichiro Tanaka, Evgueni L. Saenko, Hiroshi Suzuki, Akira Yoshioka, K. Nogami
Publikováno v:
Journal of Thrombosis and Haemostasis. 4:1354-1360
Factor (F)V is converted into its active form, FVa, by limited proteolysis. Thrombin-catalyzed activation of FV is essential for its full cofactor activation. Previously, we reported that thrombin was bound to the C2 domain in the light chain of FVII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a7772846a1ed79cabb051d80009585a
https://doi.org/10.1111/j.1538-7836.2006.01957.x
https://doi.org/10.1111/j.1538-7836.2006.01957.x